Ghana, Senegal, Rwanda signs partnership to produce vaccines for Covid-19, Malaria & Tuberculosis
Ghana, Rwanda and Senegal, on Wednesday, 16th February 2022, entered into a joint partnership with German biotechnology company, BioNTech SE, to manufacture, fill, finish, and package BioNTech mRNA vaccines for COVID-19, Malaria and Tuberculosis in Africa.
The partnership is a first step in the chain of domestic vaccine production which will to improve vaccine supply in Africa.
Commercial production of vaccines is expected to begin in 2023.
The first modular vaccine production facility (BioNTainer) is expected to be shipped in mid-2022.
BioNTech will ship BioNTainers to Rwanda and Senegal, and Ghana will support the manufacturing with fill-and-finish capacities.
Vaccines manufactured in these facilities are expected to be dedicated to domestic use and export to other member states of the African Union at a not-for-profit price.